A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differences

Health Policy

Volumn 79, Issue 2-3, 2006, Pages 214-220

  Lexchin, Joel ^a,b,c  

^a YORK UNIVERSITY   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Canada; Food and Drug Administration; Prescription medications; Therapeutic Products Directorate; Therapeutic value; United States

Indexed keywords

ABARELIX; AGALSIDASE ALFA; ALPRAZOLAM; ANTIEMETIC AGENT; ATAZANAVIR; AZELAIC ACID; BEVACIZUMAB; CARBIDOPA; CYCLOSPORIN; DAPTOMYCIN; EFALIZUMAB; EMTRICITABINE; ENTACAPONE; EPINASTINE; EPLERENONE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FLUOROURACIL; FLUOXETINE; GATIFLOXACIN; INFLUENZA VACCINE; LEVODOPA; MEMANTINE; MOXIFLOXACIN; OLANZAPINE; OMALIZUMAB; OXYBUTYNIN; PALONESETRON; PEDIARIX; PEMETREXED; PENTAVALENT VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE;

ALLERGIC CONJUNCTIVITIS; ALZHEIMER DISEASE; ARTICLE; CANADA; COLON CANCER; CONJUNCTIVITIS; DATA BASE; DEPRESSION; DRUG APPROVAL; DRUG MARKETING; DRY EYE; FABRY DISEASE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; INFLUENZA; MEDICAL INFORMATION; PANIC; PARKINSON DISEASE; PHARMACOLOGY; PROSTATE CANCER; PSORIASIS; ROSACEA; SKIN INFECTION; TREATMENT INDICATION; UNITED STATES;

CANADA; DRUG APPROVAL; HUMANS; PHARMACEUTICAL PREPARATIONS; REVIEW LITERATURE; REVIEW LITERATURE AS TOPIC; UNITED STATES;

EID: 33749527199     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2005.12.015     Document Type: Article

References (20)

1. Rawson N. Timeliness of review and approval of new drugs in Canada from 1999 through 2001: is progress being made?. Clinical Therapeutics 25 (2003) 1230-1247
2. Canada's Research-Based Pharmaceutical Companies. Drug approval times in Canada. http://www.canadapharma.org/Industry_Publications/Fact_Sheets/drugapprovaltimes_01_e.pdf; 2001 [accessed March 27, 2005].
3. Graham J.R. Prescription drug prices in Canada and the United States-Part 4: Canadian prescriptions for American patients are not the solution (September 2003), Fraser Institute, Vancouver
4. Patented Medicine Prices Review Board. PMPRB annual report 2003. Ottawa: PMPRB; 2004.
5. Patented Medicine Prices Review Board. Annual report 2001. Ottawa: PMPRB; 2002.
6. Drugs in 2001: a number of ruses unveiled. Prescrire International 2002;11:58-60.
7. Therapeutic Products Directorate: TPD-Web. Special access programme-drugs; 2002. http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/sap_factsheet2002_e.html [accessed February 18, 2005].
8. Who we are. The Medical Letter. http://www.medletter.com/html/who.htm; 2005 [accessed December 21, 2005].
9. Therapeutic Products Directorate: TPD-Web. Notice of compliance listings. http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/index_drugs_noc_e.html - 2004; 2005 [accessed March 15, 2005].
10. Patented Medicine Prices Review Board. Legislation, regulations and guidelines: compendium of guidelines, policies and procedures; 2004. http://www.pmprb-cepmb.gc.ca/english/View.asp?x=135&mp=73 [accessed March 27, 2005].
11. Center for Drug Evaluation and Research. Manual of policies and procedures (MaPPs). Food and Drug Administration. http://www.fda.gov/cder/regulatory/default.htm; 2005 [accessed March 27, 2005].
12. Food and Drug Administration. FY 2003 performance report to the president and the congress. Appendix B: list of approved applications. http://www.fda.gov/oc/pdufa/report2003/appendixb2003.html; 2005 [accessed February 18, 2005].
13. Center for Drug Evaluation and Research. Drugs @ FDA. Food and Drug Administration. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?CFID=5590034&CFTOKEN=16354048; 2005 [accessed March 27, 2005].
14. Stat View 5.0.1. Cary, NC: SAS Institute Inc.; 1999.
15. Landis J.R., and Koch G.G. The measurement of observer agreement for categorical data. Biometrics 33 (1977) 159-174
16. Center for Drug Evaluation and Research. NDAs approved in calendar years 1990-2003 by therapeutic potentials and chemical types; 2004. http://www.fda.gov/cder/rdmt/pstable.htm [accessed February 14, 2005].
17. Yasuda S.U., and Woosley R.L. The clinical value of FDA class C drugs approved from 1981 to 1988. Clinical Pharmacology and Therapeutics 52 (1992) 577-582
18. Ursodeoxycholic acid. Primary biliary cirrhosis: dashed hopes. Prescrire International 2002;11:67-9.
19. Tomalin A. A quick trip to the market: ten simple steps to hasten approval times for new drugs in Canada. Canadian Pharmaceutical Marketing winter (2000) 27-29
20. Rawson N.S.B., and Kaitin K.I. Canadian and US drug approval times and safety considerations. Annals of Pharmacotherapy 37 (2003) 1403-1408